Ajinomoto Co., Ltd.

Yukitsugu Ono

Akira Takahara

Seiji Niwa

Tomoko Takeda

Hajime Koganei

Seiji Ohno

Morikazu Kito

Shinichi Fujita

Satoshi Iwayama

Kayo Otani

Takashi Yamamoto

Yuki Kajigaya

Masako Hagihara

Akiko Okajima

Keiko Moki

Seiichi Sato

Koichi Ishii

Tomoyuki Onishi

Naoyuki Fukuchi

Munetaka Tokumasu

Hiroyuki Matsueda

Hisayuki Uneyama

Yasuko Jojima

Yoko Masuzawa

Akiko Tanaka

Fumie Futaki

Junko Shinozaki

Takayuki Kajiura

Chika Nakanishi

Akira Nakajo

The invention relates to a compound represented by the following general formula (1) or its analogue, which selectively inhibit N-type calcium channels or its analogue, and to a method for treating pain etc. comprising the compound represented by the following general formula (1) or its analogue to a patient in need of such treatment: wherein, A represents CH&#x2550;CH, etc., a, b, c and d represents CH etc., R1, R2, R3, R4, R5 and R6 represents H etc., V&#x2014;W represents C&#x2550;C, etc., n represents 0 to 3, Y1 represents O etc., B represents &#x2014;(CH2)vCHR21 wherein v is 0 to 3, R21 represents H, a lower alkyl group or the like, etc., G represents &#x2014;CO&#x2014;, a covalent bond, etc., m is 0 to 6, R7 and R8 represents H, a lower alkyl group, &#x2014;COR18a, &#x2014;COOR20 wherein R18a and R20 each represents a lower alkyl group or the like, etc.

Diarylalkene derivatives and novel diarylalkane derivatives

A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.

Substance with antithrombotic activity and method for detecting glycokallidin

Achiral pyrimidine derivatives and pyridine derivatives of the following formulae or analogs thereof have selective N-type calcium channel antagonistic activity and showed analgesic action when they were taken orally. They are useful as therapeutic agents for pains and various diseases associated with the N-type calcium channels. 

Pyridine compounds useful as N-type calcium channel antagonists

Achiral pyrimidine derivatives and pyridine derivatives of the following formulae or analogs thereof have selective N-type calcium channel antagonistic activity and showed analgesic action when they were taken orally. They are useful as therapeutic agents for pains and various diseases associated with the N-type calcium channels 

Pyrimidine compounds useful as N-type calcium channel antagonists

Compounds having a selective N-type calcium channel antagonistic activity are provided. Dihydropyridine derivatives represented by the following formula: analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel, and they are used as therapeutic agents for various diseases relating to N-type calcium channel.

Dihydropyridine derivatives

Dihydropyrimidine derivatives of the following formula or analogs thereof have selective N-type calcium channel antagonistic activity, and they are used as therapeutic agents for various diseases participating in the N-type calcium channels.

Dihydropyrimidine compounds and compositions containing the same

Dihydropyridine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel. They are used as remedies for various diseases relating to the N-type calcium channel.

Dihydropyridine derivative

Growing community of inventors

Kawasaki, Japan

Yukitsugu Ono